Literature DB >> 12782763

Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer.

D Grammatopoulos1, Y Elliott, S C Smith, I Brown, R J Grieve, E W Hillhouse, M A Levine, M D Ringel.   

Abstract

AIMS: Monitoring treated patients with thyroid cancer for recurrent or metastatic disease is currently based upon the serial measurement of circulating plasma thyroglobulin (Tg) concentrations. However, the clinical usefulness of Tg immunoassays is limited by poor sensitivity and interference from anti-Tg antibodies. This study investigated whether the detection of Tg mRNA in peripheral blood, using reverse transcriptase polymerase chain reaction (RT-PCR), is of value in the biochemical surveillance of patients with thyroid cancer.
METHODS: RNA was extracted from peripheral blood of five normal controls, six patients with abnormal thyroid function tests, and 28 patients who had undergone thyroidectomy for well differentiated thyroid cancer. From each, an 87 bp product from base pair 262 to 348 in the cDNA sequence of the thyroglobulin gene was amplified by RT-PCR.
RESULTS: Tg mRNA was detected in normal individuals and patients with thyroid cancer. In the group of patients studied, identification of metastatic thyroid tissue by radioiodine scanning correlated better with Tg mRNA assay results than with serum Tg concentrations (accuracy 84% v 75%). No interference from circulating Tg antibodies was apparent. In patients studied prospectively over a 12 month period, there was a significant correlation between detectable Tg mRNA in peripheral blood and the presence or absence of metastatic disease, as demonstrated by radioiodine scanning.
CONCLUSIONS: These results suggest that detection of Tg mRNA in blood is a more sensitive marker for metastatic thyroid disease than Tg immunoassay, and appears to be unaffected by the presence of circulating anti-Tg antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782763      PMCID: PMC1187312          DOI: 10.1136/mp.56.3.162

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  25 in total

1.  Isoelectric focusing and immunoblotting analysis of thyroglobulin from different thyroid diseases.

Authors:  A Olivieri; A Marzullo; G B Salabé; E Gilardi; C Fazzini; S Carta
Journal:  Thyroidology       Date:  1991-01

2.  Quantitative reverse transcription-PCR measurement of thyroglobulin mRNA in peripheral blood of healthy subjects.

Authors:  S T Wingo; M D Ringel; J S Anderson; A D Patel; Y D Lukes; Y Y Djuh; B Solomon; D Nicholson; P L Balducci-Silano; M A Levine; G L Francis; R M Tuttle
Journal:  Clin Chem       Date:  1999-06       Impact factor: 8.327

3.  Serum thyroglobulin concentrations and 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy).

Authors:  F Pacini; A Pinchera; C Giani; L Grasso; L Baschieri
Journal:  Clin Endocrinol (Oxf)       Date:  1980-07       Impact factor: 3.478

4.  Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.

Authors:  M D Ringel; P L Balducci-Silano; J S Anderson; C A Spencer; J Silverman; Y H Sparling; G L Francis; K D Burman; L Wartofsky; P W Ladenson; M A Levine; R M Tuttle
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

5.  Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction.

Authors:  B Smith; P Selby; J Southgate; K Pittman; C Bradley; G E Blair
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

6.  Serum thyroglobulin measurements in thyroid cancer: evaluation of 'false' positive results.

Authors:  E G Black; M C Sheppard
Journal:  Clin Endocrinol (Oxf)       Date:  1991-12       Impact factor: 3.478

7.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

8.  Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.

Authors:  M Ozata; S Suzuki; T Miyamoto; R T Liu; F Fierro-Renoy; L J DeGroot
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

9.  Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay.

Authors:  A E Katz; C A Olsson; A J Raffo; C Cama; H Perlman; E Seaman; K M O'Toole; D McMahon; M C Benson; R Buttyan
Journal:  Urology       Date:  1994-06       Impact factor: 2.649

10.  Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR.

Authors:  J Bojunga; S Röddiger; M Stanisch; K Kusterer; R Kurek; H Renneberg; S Adams; E Lindhorst; K H Usadel; P M Schumm-Draeger
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  4 in total

1.  Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.

Authors:  B Gibelli; P Tredici; C De Cicco; L Bodei; M T Sandri; G Renne; R Bruschini; N Tradati
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Large discrepancy in the results of sensitive measurements of thyroglobulin antibodies in the follow-up on thyroid cancer: a diagnostic dilemma.

Authors:  Birte Nygaard; Jens Bentzen; Peter Laurberg; Susanne Møller Pedersen; Lars Bastholt; Aase Handberg; Carsten Rytter; Christian Godballe; Jens Faber
Journal:  Eur Thyroid J       Date:  2012-08-14

3.  Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin.

Authors:  I G S Rubio; M N C Silva; M Knobel; R Romão; R Possato; E M M S Gebrin; C Buchpiguel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

4.  Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.

Authors:  E Hesse; P B Musholt; E Potter; T Petrich; M Wehmeier; R von Wasielewski; R Lichtinghagen; T J Musholt
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.